United Therapeutics Corporation

Equities

UTHR

US91307C1027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
264.3 ^USD	-0.67%		+0.71%	+20.18%

May. 10	United Therapeutics Insider Sold Shares Worth $1,898,393, According to a Recent SEC Filing	MT
May. 08	United Therapeutics Insider Sold Shares Worth $949,737, According to a Recent SEC Filing	MT

United Therapeutics Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2023

November 01, 2023 at 06:00 am EDT

United Therapeutics Corporation reported earnings results for the third quarter ended September 30, 2023. For the third quarter, the company reported sales was USD 609.4 million compared to USD 516 million a year ago. Net income was USD 267.6 million compared to USD 239.3 million a year ago.

Basic earnings per share from continuing operations was USD 5.71 compared to USD 5.26 a year ago. Diluted earnings per share from continuing operations was USD 5.38 compared to USD 4.91 a year ago.

Latest news about United Therapeutics Corporation

United Therapeutics Insider Sold Shares Worth $1,898,393, According to a Recent SEC Filing	May. 10	MT
United Therapeutics Insider Sold Shares Worth $949,737, According to a Recent SEC Filing	May. 08	MT
United Therapeutics Insider Sold Shares Worth $1,871,233, According to a Recent SEC Filing	May. 07	MT
United Therapeutics Insider Sold Shares Worth $2,585,601, According to a Recent SEC Filing	May. 06	MT
United Therapeutics Insider Sold Shares Worth $582,195, According to a Recent SEC Filing	May. 06	MT
United Therapeutics Insider Sold Shares Worth $1,829,903, According to a Recent SEC Filing	May. 03	MT
UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating	May. 02	MT
Oppenheimer Adjusts United Therapeutics Price Target to $400 From $375, Maintains Outperform Rating	May. 02	MT
Transcript : United Therapeutics Corporation, Q1 2024 Earnings Call, May 01, 2024	May. 01
United Therapeutics Q1 Net Income, Revenue Advance; Shares Rise Pre-Bell	May. 01	MT
Earnings Flash (UTHR) UNITED THERAPEUTICS CORPORATION Reports Q1 Revenue $677.7M, vs. Street Est of $624.2M	May. 01	MT
Tranche Update on United Therapeutics Corporation's Equity Buyback Plan announced on March 25, 2024.	May. 01	CI
United Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
United Therapeutics Insider Sold Shares Worth $1,704,174, According to a Recent SEC Filing	Apr. 23	MT
United Therapeutics Q1 Results Could Fall Short of Market Expectations, Oppenheimer Says	Apr. 23	MT
United Therapeutics Insider Sold Shares Worth $1,704,990, According to a Recent SEC Filing	Apr. 19	MT
United Therapeutics Insider Sold Shares Worth $1,682,819, According to a Recent SEC Filing	Apr. 17	MT
United Therapeutics Insider Sold Shares Worth $1,707,775, According to a Recent SEC Filing	Apr. 15	MT
United Therapeutics Insider Sold Shares Worth $6,831,737, According to a Recent SEC Filing	Apr. 11	MT
United Therapeutics Insider Sold Shares Worth $4,727,736, According to a Recent SEC Filing	Apr. 09	MT
United Therapeutics Insider Sold Shares Worth $6,957,709, According to a Recent SEC Filing	Apr. 05	MT
United Therapeutics Insider Sold Shares Worth $1,394,248, According to a Recent SEC Filing	Apr. 04	MT
Liquidia Says US FDA Cleared to Approve Yutrepia to Treat Hypertension	Apr. 01	MT
Liquidia's Yutrepia Cleared for Potential FDA Approval Following Court Ruling	Apr. 01	DJ
United Therapeutics Corporation Announces Extension of Credit Agreement	Mar. 29	CI

Chart United Therapeutics Corporation

Duration

Period

More charts

Company Profile

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.

Sector

Biotechnology & Medical Research

Calendar

2024-05-19 - American Thoracic Society Conference - Aaron B. Waxman

More about the company

Income Statement Evolution

More financial data

Ratings for United Therapeutics Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

264.3 USD

Average target price

292.7 USD

Spread / Average Target

+10.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
UNITED THERAPEUTICS CORPORATION	+20.18%	11.72B
MODERNA, INC.	+17.96%	44.96B
LONZA GROUP AG	+48.77%	41.85B
IQVIA HOLDINGS INC.	+1.17%	42.65B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research